Focus: Vedanta Biosciences is a microbiome-focused biotech company developing therapies that modulate interactions between the human microbiome and host immune system, primarily in gastroenterology. The company is pre-revenue and at clinical development stage with a diversified pipeline spanning multiple indications.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Vedanta offers intellectually compelling microbiome science and Phase 3 upside, but early-stage risk profile and hiring freeze signal near-term uncertainty—best suited for risk-tolerant early-career or mid-career scientists seeking platform exploration.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vedanta Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vedanta Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Fierce Biotech Layoff Tracker 2026: Autolus decreases headcount by 13%; Replimune reduces staff - Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Autolus decreases headcount by 13%; Replimune reduces staff Fierce Biotech
Convergent Therapeutics Taps Andrew Davis as Chief Business and Strategy Officer - Contract Pharma
Convergent Therapeutics Taps Andrew Davis as Chief Business and Strategy Officer Contract Pharma
Clostridium Difficile Infections Pipeline Set for Transformational Growth by 2026 with 22+ Therapies and Strong Clinical Momentum from Vedanta Biosciences, Acurx Pharmaceuticals | DelveInsight - Barchart.com
Clostridium Difficile Infections Pipeline Set for Transformational Growth by 2026 with 22+ Therapies and Strong Clinical Momentum from Vedanta Biosciences, Acurx Pharmaceuticals | DelveInsight Barchart.com
Human Microbiome Therapeutics Market Size, Share, Growth - openPR.com
Human Microbiome Therapeutics Market Size, Share, Growth openPR.com
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 The Business Journals
8-K Filing: Harmony Biosciences Holdings, Inc. (HRMY) (CIK 0001802665) — 8-K
8-K
Showing 6 of 7 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adults.
Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo